These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174 [TBL] [Abstract][Full Text] [Related]
23. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881 [TBL] [Abstract][Full Text] [Related]
24. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians. Peshkin BN; Isaacs C; Finch C; Kent S; Schwartz MD J Clin Oncol; 2003 Dec; 21(23):4322-8. PubMed ID: 14645421 [TBL] [Abstract][Full Text] [Related]
25. The role of ovarian ablation in the management of breast cancer. Wirk B Breast J; 2005; 11(6):416-24. PubMed ID: 16297086 [TBL] [Abstract][Full Text] [Related]
26. Management of hereditary breast and ovarian cancer. Yamauchi H; Takei J Int J Clin Oncol; 2018 Feb; 23(1):45-51. PubMed ID: 29185095 [TBL] [Abstract][Full Text] [Related]
27. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Narod SA; Brunet JS; Ghadirian P; Robson M; Heimdal K; Neuhausen SL; Stoppa-Lyonnet D; Lerman C; Pasini B; de los Rios P; Weber B; Lynch H; Lancet; 2000 Dec; 356(9245):1876-81. PubMed ID: 11130383 [TBL] [Abstract][Full Text] [Related]
28. Future possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers. Eeles RA Breast Cancer Res; 2000; 2(4):283-90. PubMed ID: 11250722 [TBL] [Abstract][Full Text] [Related]
29. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future. Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443 [TBL] [Abstract][Full Text] [Related]
30. Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting. Morgan D; Sylvester H; Lucas FL; Miesfeldt S Fam Cancer; 2009; 8(4):277-87. PubMed ID: 19347608 [TBL] [Abstract][Full Text] [Related]
31. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted? McGee J; Giannakeas V; Karlan B; Lubinski J; Gronwald J; Rosen B; McLaughlin J; Risch H; Sun P; Foulkes WD; Neuhausen SL; Kotsopoulos J; Narod SA; Gynecol Oncol; 2017 May; 145(2):346-351. PubMed ID: 28314588 [TBL] [Abstract][Full Text] [Related]
32. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605 [TBL] [Abstract][Full Text] [Related]
33. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175 [TBL] [Abstract][Full Text] [Related]
34. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Ludwig KK; Neuner J; Butler A; Geurts JL; Kong AL Am J Surg; 2016 Oct; 212(4):660-669. PubMed ID: 27649974 [TBL] [Abstract][Full Text] [Related]
35. Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review. Li X; You R; Wang X; Liu C; Xu Z; Zhou J; Yu B; Xu T; Cai H; Zou Q Clin Cancer Res; 2016 Aug; 22(15):3971-81. PubMed ID: 26979395 [TBL] [Abstract][Full Text] [Related]
36. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL; N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993 [TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers. Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095 [TBL] [Abstract][Full Text] [Related]
39. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer. Kuschel B; Lux MP; Goecke TO; Beckmann MW Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253 [TBL] [Abstract][Full Text] [Related]
40. Therapeutic approaches for women predisposed to breast cancer. Nathanson KL; Domchek SM Annu Rev Med; 2011; 62():295-306. PubMed ID: 21034216 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]